Bruce leads Value Genome’s Health Economics and Outcomes Research practice where he specializes in health economic modeling, database analysis, and evidence generation.
He was also CEO and Co-Founder of Elysia Group, LLC until the firm was acquired by Real Chemistry.
Bruce established the HEOR practice as Vice President of Health Economics for Alliance Life Sciences Consulting Group, which was later acquired by Eversana.
Bruce begin his career as a Macroeconomic Strategist for Goldman Sachs in New York.
He has served on the faculties of the University of Washington and Taipei Medical University.
Bruce obtained his doctoral degree in Economics for the University of Washington and did his undergraduate work at Columbia University.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.